Healthcare Industry News: metabolic disease
News Release - December 12, 2006
Ilypsa Announces Promotion of Gerrit Klaerner, Ph.D. to Senior Vice President and Chief Business OfficerSANTA CLARA, Calif.--(HSMN NewsFeed)--Ilypsa, Inc, a privately-held biopharmaceutical company pioneering novel non-absorbed drugs for renal disorders, today announced the promotion of Gerrit Klaerner, Ph.D., to the position of Senior Vice President and Chief Business Officer.
"Gerrit assumes this role in recognition of his excellent track record of strategic and operational leadership since his co-founding of Ilypsa in 2003," said Jay Shepard, President and Chief Executive Officer of Ilypsa. "Gerrit also lead the formation of strategic business alliances with Astellas and Cubist, and his insight will continue to be invaluable at a time when the company is advancing a promising pipeline and considering a number of strategic and funding opportunities."
"We have established a strong team and have successfully grown Ilypsa from a company with a unique platform and initial ideas for advanced, non-absorbed polymeric drugs to a company with five products, one of which is in Phase 2 clinical trials," said Dr. Klaerner. "Ilypsa is well positioned to capitalize on business opportunities arising from our great science and efficient product development."
Dr. Klaerner co-founded Ilypsa in 2003 while at Symyx Technologies. Dr. Klaerner joined Symyx in 1998 as a staff scientist, and was later promoted to Director of Business Development. While there, he was responsible for initiating several life science programs including a strategic alliance and late-stage licensing agreement with Applied Biosystems for novel DNA sequencing media and Symyx's first product -- a novel surface for DNA and protein arrays. Dr. Klaerner received his Ph.D. in polymer chemistry from the Max-Planck-Institute for Polymer Research in Mainz, Germany. He conducted postdoctoral research at Stanford University and the IBM Almaden Research Center.
About Ilypsa, Inc.
Ilypsa, Inc. is a privately held biopharmaceutical company discovering and developing a pipeline of next-generation renal care pharmaceutical products. Pioneering the use of a proprietary high throughput discovery and development platform created and validated at Symyx Technologies, Inc. (NASDAQ: SMMX ), Ilypsa has rapidly created non-absorbed polymeric phosphate and potassium binder compounds to treat chronic kidney disease, and has additional programs in kidney, infectious and metabolic diseases. To date, Ilypsa has raised $46 million in a Series A and Series B round of financing. Investors include The Sprout Group, 5AM Ventures, US Venture Partners, Johnson & Johnson Development Corporation and Delphi Ventures. For more information, please visit www.ilypsa.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.